ABL1 and acute lymphoblastic leukemia: In the past decade, tremendous progress has been made in the treatment of ALL with the development of targeted therapies, including tyrosine kinase inhibitors of BCR::ABL1, monoclonal antibodies, bispecific antibodies (BsAb), and chimeric antigen receptor T- cell therapy targeting cell surface antigens [2].